Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07905428 topical solution in acne vulgaris
NCT06671834Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07905428 in acne vulgaris (3 arms), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events at 2 months, Serious Adverse Events at 2 months and 3 more. Started Nov 2024; status: completed.
02
Drugs
PF-07905428
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06671834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671834.